Features of aggregometry indicators in male residents of the Stavropol Territory — representatives of the Russian and Armenian ethnic groups receiving hospital treatment

Relevance. The scale of use of acetylsalicylic acid is determined by its use as a means of suppressing platelet aggregation in patients with coronary heart disease. It has been established that the antiplatelet effect in some patients may be weak and insufficient to prevent thrombosis. In this regard, the problem of resistance to acetylsalicylic acid requires more detailed study. Objective. To study the influence of acetylsalicylic acid on aggregometry indicators in men with the same body weight, belonging to the Russian and Armenian ethnic groups of residents of the Stavropol Territory, who were treated in a specialized hospital. Material and methods. Men who were treated in the following hospital departments were examined: cardiology department; department of acute coronary syndrome, and department of acute cerebrovascular accidents. Russian ethnic group — 53, Armenian — 24 patients. When forming groups, a body mass index in the range of 33.0±3.9 was considered to be selected patients with similar body weight. Patients received 75 or 100 mg of acetylsalicylic acid per day. In the department of acute coronary syndrome, acetylsalicylic acid was used along with clopidogrel — 75 mg per day. Aggregatometry was performed after 5 days of regular antiplatelet therapy. Results. In men of the Russian ethnic group who received acetylsalicylic acid at a daily dose of 75 mg, the amplitude of ADP-induced aggregation was statistically significantly higher (Me=13.9 %) than in the Armenian group (Me = 3.0) (p = 0.024). Armenians showed smaller amplitudes of aggregation during induction with ristomycin (33.3 %) than Russians (52.7 %). When using acetylsalicylic acid at a higher dose (100 mg per day), as well as when prescribing two antiplatelet agents, the differences between ethnic groups decreased. Conclusion. When using acetylsalicylic acid at a dose of 75 mg/day in sick men of the Russian ethnic group, insufficient antiplatelet activity of the drug can be expected.